Ipca shares down 14% at 52-week low on fallout of USFDA warning
The shares of Ipca Laboratories slumped over 14 percent as Switzerland-based Global Fund, which financially supports various disease eradication programmes, decided it will not source its malaria drug, the company notified the BSE.
Apr 08, 2016, 15:52 PM IST